The stock of Athersys, Inc. (NASDAQ:ATHX) is a huge mover today! The stock decreased 3.29% or $0.07 during the last trading session, hitting $2.06. About 414,849 shares traded hands or 27.92% up from the average. Athersys, Inc. (NASDAQ:ATHX) has risen 10.16% since March 1, 2016 and is uptrending. It has underperformed by 2.06% the S&P500.
The move comes after 7 months negative chart setup for the $180.14M company. It was reported on Oct, 4 by Barchart.com. We have $1.81 PT which if reached, will make NASDAQ:ATHX worth $21.62 million less.
Analysts await Athersys, Inc. (NASDAQ:ATHX) to report earnings on November, 3. They expect $-0.11 EPS, down 37.50% or $0.03 from last year’s $-0.08 per share. After $-0.08 actual EPS reported by Athersys, Inc. for the previous quarter, Wall Street now forecasts 37.50% negative EPS growth.
According to Zacks Investment Research, “Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The company’s lead product candidate, ATHX-105, is an oral, selective 5HT2c receptor agonist in Phase I clinical trials for the treatment of obesity. The company is also developing other orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE). Athersys is developing MultiStem(r), its patented, adult-derived “off the shelf” stem cell product platform, for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications.”
Insitutional Activity: The institutional sentiment decreased to 2.14 in Q2 2016. Its down 0.32, from 2.46 in 2016Q1. The ratio dropped, as 12 funds sold all Athersys, Inc. shares owned while 10 reduced positions. 23 funds bought stakes while 24 increased positions. They now own 14.56 million shares or 52.63% more from 9.54 million shares in 2016Q1.
Royal Fincl Bank Of Canada holds 0% or 2,082 shares in its portfolio. Bnp Paribas Arbitrage, a New York-based fund reported 3,011 shares. Umb Comml Bank N A Mo last reported 0% of its portfolio in the stock. The California-based Parallax Volatility Advisers Limited Partnership has invested 0% in Athersys, Inc. (NASDAQ:ATHX). Voya Inv Limited Liability Corp reported 36,348 shares or 0% of all its holdings. Millennium Ltd Company holds 0% or 68,443 shares in its portfolio. Blair William Co Il has 10,000 shares for 0% of their US portfolio. Principal Fincl Gp has 12,595 shares for 0% of their US portfolio. Art Advsr Limited Liability holds 0.01% of its portfolio in Athersys, Inc. (NASDAQ:ATHX) for 69,953 shares. Lpl Finance Limited Liability Corp holds 109,000 shares or 0% of its portfolio. Deutsche State Bank Ag reported 18,952 shares or 0% of all its holdings. Cambridge Invest, a Iowa-based fund reported 25,000 shares. Rhumbline Advisers holds 74,382 shares or 0% of its portfolio. Blackrock has invested 0% of its portfolio in Athersys, Inc. (NASDAQ:ATHX). Blackrock Institutional Na accumulated 0% or 859,172 shares.
Insider Transactions: Since September 15, 2016, the stock had 0 insider purchases, and 2 insider sales for $35,323 net activity. $29,449 worth of Athersys, Inc. (NASDAQ:ATHX) was sold by Harrington John J. Lehmann William JR had sold 3,000 shares worth $5,874.
ATHX Company Profile
Athersys, Inc., incorporated on June 7, 2005, is an international biotechnology firm that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. The Company’s activities consist primarily of research and product development activities. The Company’s clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients. MultiStem treatment enhances tissue repair and healing in multiple ways, including reducing inflammatory damage, protecting tissue that is at risk following acute or ischemic injury, and promoting formation of new blood vessels in regions of ischemic injury. These cells appear to be responsive to the environment in which they are administered, by homing to sites of injury and/or organs involved in injury response, and providing active disease response, while producing proteins that may provide benefit in both acute and chronic conditions.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.